IS1846B - Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur - Google Patents

Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur

Info

Publication number
IS1846B
IS1846B IS4345A IS4345A IS1846B IS 1846 B IS1846 B IS 1846B IS 4345 A IS4345 A IS 4345A IS 4345 A IS4345 A IS 4345A IS 1846 B IS1846 B IS 1846B
Authority
IS
Iceland
Prior art keywords
alaninamide
indole
carbonyl
substituted
drug formulations
Prior art date
Application number
IS4345A
Other languages
English (en)
Other versions
IS4345A (is
Inventor
Hulin Bernard
Lee Treadway Judith
Holt Martin William
Jay Hoover Dennis
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4345A publication Critical patent/IS4345A/is
Publication of IS1846B publication Critical patent/IS1846B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS4345A 1995-06-06 1996-05-13 Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur IS1846B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002223625A CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
IS4345A IS4345A (is) 1996-12-07
IS1846B true IS1846B (is) 2003-02-07

Family

ID=25679897

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4345A IS1846B (is) 1995-06-06 1996-05-13 Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur

Country Status (40)

Country Link
US (1) US6297269B1 (is)
EP (1) EP0832066B1 (is)
JP (1) JP3068200B2 (is)
CN (1) CN1374082A (is)
AP (2) AP9600817A0 (is)
AT (1) ATE205477T1 (is)
AU (1) AU700887B2 (is)
BG (1) BG62566B1 (is)
BR (1) BR9602626A (is)
CA (1) CA2223625C (is)
CO (1) CO4700453A1 (is)
CZ (1) CZ289233B6 (is)
DE (1) DE69522718T2 (is)
DK (1) DK0832066T3 (is)
DZ (1) DZ2036A1 (is)
ES (1) ES2161291T3 (is)
FI (1) FI974437A7 (is)
GR (1) GR3037075T3 (is)
HR (1) HRP960266B1 (is)
HU (1) HUP9601285A3 (is)
IL (1) IL118236A0 (is)
IS (1) IS1846B (is)
LV (1) LV11614B (is)
MA (1) MA23874A1 (is)
MX (1) MX9709874A (is)
NO (1) NO307335B1 (is)
NZ (1) NZ286736A (is)
OA (1) OA10459A (is)
PL (1) PL314603A1 (is)
PT (1) PT832066E (is)
RU (1) RU2159613C2 (is)
SG (1) SG45481A1 (is)
SI (1) SI9600163A (is)
SK (1) SK72096A3 (is)
TN (1) TNSN96075A1 (is)
TR (1) TR199600478A1 (is)
TW (1) TW450961B (is)
WO (1) WO1996039385A1 (is)
YU (1) YU34796A (is)
ZA (1) ZA964646B (is)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
SK141899A3 (en) 1997-04-15 2000-09-12 Csir Corporate Building Pharmaceutical compositions having appetite suppressant activity
TR199903057T2 (xx) * 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6096778A (en) * 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
EP1147214B1 (en) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
PT1088824E (pt) * 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
SK6052002A3 (en) 1999-11-04 2003-09-11 Ortho Mcneil Pharm Inc Nonpeptide substituted benzothiazepines as vasopressin antagonists
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
AU2002214222A1 (en) * 2000-11-01 2002-05-15 Yeda Research And Development Co..Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
US6821960B2 (en) * 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030037045A1 (en) * 2001-05-21 2003-02-20 Ian Melhado Distributed computing environment for recognition of proteomics spectra
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP4623962B2 (ja) 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
WO2003037864A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
EP2769715A3 (en) 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JP4771661B2 (ja) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
CA2472205A1 (en) * 2002-01-18 2003-07-24 Frank Robert Busch Intermediates for preparing glycogen phosphorylase inhibitors
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
DE50311923D1 (de) * 2002-07-11 2009-10-29 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2495943C (en) * 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
AU2003274462A1 (en) * 2002-11-07 2004-06-07 Pfizer Products Inc. N-(indole-2-carbonyl) amides as anti-diabetic agents
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
FR2847471B1 (fr) * 2002-11-25 2006-12-29 Expanscience Lab Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
CA2522225A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
WO2004096768A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
EP1636224B1 (en) * 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
TWI324600B (en) * 2003-07-07 2010-05-11 Kowa Co 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2004288831B2 (en) 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
RU2382780C2 (ru) * 2004-02-27 2010-02-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы каспаз и их применение
US20080188472A1 (en) * 2004-03-08 2008-08-07 Prosidion Limited Indole-2-Carboxylic Acid Hydrazides
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
ES2328384T3 (es) 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN102351791B (zh) * 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
DE102006042147A1 (de) * 2006-09-06 2008-03-27 Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden
MEP8509A (en) 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
EP2069289B1 (de) * 2006-09-13 2013-10-02 Sanofi ISOSERINDERIVATE ALS INHIBITOREN DES KOAGULATIONSFAKTORS IXa
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
EP2368560A1 (en) 2007-03-12 2011-09-28 Zadec ApS An anti-diabetic extract of rooibos
SG188117A1 (en) 2008-06-19 2013-03-28 Takeda Pharmaceutical Heterocyclic compound and use thereof
CA2738573C (en) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
ES2653215T3 (es) 2011-05-31 2018-02-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
ES2699773T3 (es) * 2011-05-31 2019-02-12 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina
CA2835281A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
EP3065723B1 (en) 2013-11-05 2020-09-23 Ben Gurion University of the Negev Research and Development Authority Compounds for the treatment of diabetes and disease complications arising from same
WO2015131113A1 (en) * 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
CN115583908B (zh) * 2021-07-05 2024-08-06 西北农林科技大学 一种吲哚甲酰胺类化合物及其制备方法和用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
SU1227198A1 (ru) * 1982-09-29 1986-04-30 Ленинградское Ордена Ленина И Ордена Трудового Красного Знамени Производственное Объединение Мясной Промышленности Способ получени полипептидов
US4933325A (en) 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4902708A (en) 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
HU204285B (en) 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
US5034376A (en) 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
EP0288965A2 (de) 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
JPH03503650A (ja) 1988-04-05 1991-08-15 アボツト・ラボラトリーズ Ｃｃｋアンタゴニストとしてのトリプトファン誘導体
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
US4904846A (en) 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
ATE118207T1 (de) 1989-12-04 1995-02-15 Searle & Co Heterozyklische acylaminodiol-beta-aminosäure- derivate.
WO1991012264A1 (fr) 1990-02-09 1991-08-22 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, leur preparation et les medicaments les contenant
JPH05504968A (ja) 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
FR2678938B1 (fr) 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (fr) 1992-09-18 1994-03-31 Japan Tobacco Inc. Derive d'alcool presentant une activite inhibant la renine et son utilisation
WO1994007815A2 (en) 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
CN1374082A (zh) 2002-10-16
AU5475396A (en) 1996-12-19
JPH11500445A (ja) 1999-01-12
EP0832066B1 (en) 2001-09-12
FI974437L (fi) 1997-12-05
BG62566B1 (bg) 2000-02-29
DE69522718D1 (en) 2001-10-18
NO307335B1 (no) 2000-03-20
ES2161291T3 (es) 2001-12-01
MX9709874A (es) 1998-03-31
CA2223625C (en) 2003-06-03
TW450961B (en) 2001-08-21
NO962322D0 (no) 1996-06-05
US6297269B1 (en) 2001-10-02
SK72096A3 (en) 1997-11-05
HRP960266A2 (en) 1997-08-31
AP9600817A0 (en) 1996-07-31
SI9600163A (en) 1997-02-28
PT832066E (pt) 2001-12-28
CA2223625A1 (en) 1996-12-12
IS4345A (is) 1996-12-07
WO1996039385A1 (en) 1996-12-12
JP3068200B2 (ja) 2000-07-24
BG100635A (bg) 1997-09-30
EP0832066A1 (en) 1998-04-01
CO4700453A1 (es) 1998-12-29
AP9600816A0 (en) 1996-07-31
HUP9601285A2 (hu) 1998-09-28
DK0832066T3 (da) 2001-11-19
FI974437A0 (fi) 1997-12-05
ZA964646B (en) 1997-12-05
DZ2036A1 (fr) 2002-10-22
MA23874A1 (fr) 1996-12-31
LV11614B (en) 1997-04-20
TR199600478A1 (tr) 1997-03-21
RU2159613C2 (ru) 2000-11-27
HRP960266B1 (en) 2002-08-31
YU34796A (sh) 1999-07-28
FI974437A7 (fi) 1997-12-05
TNSN96075A1 (fr) 2005-03-15
SG45481A1 (en) 1998-01-16
NO962322L (no) 1996-12-09
DE69522718T2 (de) 2002-02-07
IL118236A0 (en) 1996-09-12
HU9601285D0 (en) 1996-07-29
BR9602626A (pt) 1998-09-01
PL314603A1 (en) 1996-12-09
ATE205477T1 (de) 2001-09-15
HUP9601285A3 (en) 2001-04-28
CZ162796A3 (en) 1996-12-11
CZ289233B6 (cs) 2001-12-12
AP624A (en) 1997-12-19
NZ286736A (en) 2001-07-27
LV11614A (lv) 1996-12-20
AU700887B2 (en) 1999-01-14
GR3037075T3 (en) 2002-01-31
OA10459A (en) 2002-03-27

Similar Documents

Publication Publication Date Title
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
NO306398B1 (no) Substituerte N-(indol-2-karbonyl) glycinamider, anvendelse derav, mellomprodukt og farmasöytisk preparat
IS4644A (is) Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO308740B1 (no) Kinazolinderivater, anvendelse derav og farmasøytisk blanding
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
NO20001045D0 (no) Nye cycliske tetrapeptidderivater og medisinsk anvendelse derav
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
NO306253B1 (no) Arylsulfonyl-hydroksamsyre-derivater, anvendelse derav og farmasöytisk preparat
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
TR199600481A2 (tr) Tedavi edici amidler.
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
DK0804078T3 (da) Sammensætning og anvendelse deraf
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
FR2779429B1 (fr) Derives d'oxindole, leurs preparations et leurs applications en therapeutique
NO980471L (no) Benzensulfonamidderivater, fremstilling derav og terapautiske anvendelser derav
NO973230D0 (no) Nye peptider, deres fremstilling og anvendelse
NO307512B1 (no) Nye indolforbindelser, farmasøytisk preparat inneholdende slike forbindelser, og deres anvendelse
NO982549D0 (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav